CNOGA Medical, a developer and manufacturer of medical devices, today announces that it has received an approval for its TensorTip™ MTX™ and VSM™ non-invasive multiple bio parameters measurement devices from the China Food and Drug Administration (CFDA).

CNOGA Medical Ltd. is expecting to launch the TensorTip™ devices during Shanghai’s CMEF exhibition, April 2016.

CNOGA TensorTip™ devices use a real time color image sensor and unique algorithms to accurately measure more than a dozen bio parameters such as fingertip blood pressure, Hemoglobin, Hematocrit and Blood Gases from the patients’ fingertip blood capillaries.

The TensorTip™ product family optionally integrates with CNOGA’s SINGULAR cloud base architecture, further enhancing the users’ control over his health and wellbeing.

Dr. Yosef Segman, Founder and CEO of CNOGA states: "Securing CFDA approval in China is a significant milestone towards achieving our long term global expansion goals."

Dr. Segman added; "China is the largest market for noninvasive e-health monitoring at home as well as hospitals and clinics. In 2014, medical device sales in China totaled CNY 255.6 billion (EUR 36 billion) a year with a yearly increase of 20%, according to the China Medical Pharmaceutical Materials Association[1].

The following milestone represents a substantial growth opportunity for CNOGA with expected commercial agreements in China valued at tens of million dollars in the upcoming year. Recently, CNOGA established a diversified presence in China with a CNOGA HQ in Shanghai and an R&D center in Changzhou, Jiangsu," concluded Dr. Segman.

TensorTip™ Matrix™ (MTX) noninvasive measurements of Hemodynamics (Pulse, Blood Pressure, Cardiac Output, stroke Volume, MAP (Mean Arterial Pressure), blood gases (pH, PCO2, PO2, CO2, O2), Blood Chemistry, Hemoglobin (Hb), Hematocrit (Hct) and Red Blood Cell (RBC).

TensorTip™ Vital Sign Monitor (VSM) Measures Vital signs such as blood pressure, Pulse and SPO2 (saturation).